E‐cigarette, or Vaping, Product Use Associated Lung Injury: Epidemiology, Challenges, and Implications With COVID‐19
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.27448 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Winny Soerianto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Curriculum in Toxicology and Environmental Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Vaping, COVID-19, Electronic Nicotine Delivery Systems, Lung Injury. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIEHS NIH HHS, The study was supported by the National Institutes of Health (grant no. R01 HL171967)..
Abstract (Originalsprache)
Background
E‐cigarette, or vaping products produce an aerosol by heating nicotine, or cannabis including tetrahydrocannabinol (THC) and cannabidiol (CBD), mixed with other chemicals that help make the aerosol. They are increasingly popular among teenagers and young adults, with a 2023 survey reporting that 2.13 million middle and high school students in the United States used e‐cigarettes within the last 30 days. The use of e‐cigarette, or vaping products could lead to an acute pulmonary inflammatory syndrome called e‐cigarette, or vaping, product use‐associated lung injury (EVALI). We review the challenges in diagnosing and treating EVALI, especially during the COVID‐19 pandemic.
Methods
We conducted a literature search on June 10, 2024 using the PubMed database. We searched for articles, case reports and CDC reports investigating the pathogenesis, treatment, and challenges of diagnosing EVALI during the COVID‐19 pandemic.
Results
The exact causes of EVALI are not completely understood, although it has been linked to the use of THC and vitamin E acetate. There are no specific biomarkers to diagnose EVALI and it is typically diagnosed through a process of eliminating other possible conditions. Eight studies detailed cases where pediatric patients were initially diagnosed with COVID‐19 or community‐acquired pneumonia, despite multiple negative COVID‐19 tests, and were later found to have EVALI.
Conclusions
After alerting the public about the removal of vitamin E acetate from vape liquids in 2020, there has been a decline in cases of EVALI, although they are still detected. Therefore, it is necessary to continue looking for diagnostic markers of EVALI and further investigate the toxicity of vapes and e‐cigarettes to prevent the recurrence of another EVALI epidemic, especially among teenagers and young adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Curriculum in Toxicology and Environmental Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Center for Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Förderung
- NHLBI NIH HHS
- NIEHS NIH HHS
- The study was supported by the National Institutes of Health (grant no. R01 HL171967).
- National Institutes of Health
Zitieren
APA
Soerianto, W., & Jaspers, I. (2025). E‐cigarette, or Vaping, Product Use Associated Lung Injury: Epidemiology, Challenges, and Implications With COVID‐19. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27448
Vancouver
Soerianto W, Jaspers I. E‐cigarette, or Vaping, Product Use Associated Lung Injury: Epidemiology, Challenges, and Implications With COVID‐19. Pediatric Pulmonology. 2025. doi:10.1002/ppul.27448
BibTeX
@article{Soerianto2025,
author = {Soerianto, Winny and Jaspers, Ilona},
title = {E‐cigarette, or Vaping, Product Use Associated Lung Injury: Epidemiology, Challenges, and Implications With COVID‐19},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.27448}
}
EUVIMED